Pharmaceutical
Group at a Glance
- 19 members
- 18 members have PhDs or MDs
What Matters to Our Clients
Deep Understanding of Technology and Industry Insight
From first-hand experience, members of our Pharmaceutical Group understand the importance of patents, trademarks, and trade secrets to pharmaceutical companies. Comprised of attorneys whohave both conducted research at and represented pharmaceutical giants and startups alike, our group also understands the interaction of patents with a range of FDA issues such as patent term extensions, non-patent exclusivities, Orange Book listing requirements, Hatch-Waxman issues, and ANDA (Abbreviated New Drug Application) litigation. Our attorneys also are experienced in handling a wide variety of licensing issues and work with our clients to license in as well as license out technology.
Our clients appreciate working with a team with the scientific training to grasp complex matters quickly. Most of our members have PhDs, and several have medical degrees. Academic backgrounds include: organic chemistry, medicinal chemistry, process chemistry, formulation chemistry, chemical biology, chemical engineering, molecular biology, biochemistry, medical biophysics, immunology, molecular genetics, toxicology, and epidemiology.
Broad Base of Experience
Intellectual property law directly shapes the business of our pharmaceutical clients. Their lifeblood is derived from maximizing the terms of their patents, and the industry’s emphasis on trademarks is perhaps second only to that of the consumer products industry.
While many law firms choose to specialize their pharmaceutical IP practice on one area or type of customer profile, our clients value the agility and creativity that our group offers. Big Pharma or startup, branded or generic, active ingredient or finished product, we have the experience to thoroughly address our clients’ requirements.
Services of our Pharmaceutical Group include: freedom to operate, due diligence, license negotiation, development, prosecution, and analysis of patent and trademark portfolios, patent interferences, counseling on strategic planning issues, lifecycle management, patent term extensions, Orange Book listing strategies, and ANDA litigation.
Areas of Expertise
Examples of our group's areas of expertise include:
- Antibodies
- Oligonucleotide chemistry
- Peptide chemistry
- Protein chemistry
- RNAi
- Combinatorial chemistry
- Formulations
- Medicinal chemistry
- Metabolites
- Polymorphs
- Process chemistry
- Drug delivery systems
- High throughput screening
- Joint venture strategies
- Licensing
- Market entry strategies
- GlaxoSmithKline
- Progenics Pharmaceuticals Inc.
- Shire Pharmaceuticals
July 2010 - Bilski decision leaves many questions unanswered for TTOs
June 2010 - Bilski ruling from US Supreme Court
July 2, 2010 - Industry Groups, Practitioners React To High Court Decision on Method Patents
July 7, 2010 - A Wolf Greenfield Webinar: Forecasting the Future of Method Patents Post-Bilski — archived replay of webinar now available
June 28, 2010 - CLIENT ALERT— Supreme Court Leaves Door Open to Business Method Patents
June 17, 2010 - WOLF GREENFIELD SEMINAR: Strategically Building and Monetizing a Patent Portfolio - replay now available
June 4, 2010 - Salix's polymorph patents for Xifaxan may be vulnerable to future challenge, experts say
May 19, 2010 - “Cephalon settlement with generic makers in Nuvigil patent suits could be delayed by ongoing antitrust litigation - experts”
April 16, 2010 - Patent Applications Must Have Separate Written Description
April 14, 2010 - CLIENT ALERT— Federal Circuit Decision Reaffirms Separate Written Description Requirement
April 2, 2010 - CLIENT ALERT— The New Biosimilar Pathway: Biologics Price Competition and Innovation Act
March 31, 2010 - Prolonging Patent: Under Wyeth, Many Patent Terms Will Be Recalculated
March 29, 2010 - Court Backs Lilly In Patent Case
February 19, 2010 - More Organizations Ask PTO to Recalculate Term Adjustments
October 15, 2009 - CLIENT ALERT — USPTO Rescinds Controversial Rules Restricting Patent Applications
October 2009 - Court Case on Patent Delays Holds Appeal for Industry
September 25, 2009 - Lack of timing awareness can mean missed revenue
September 24, 2009 - CLIENT ALERT — Federal Circuit Confirms Diagnostic and Therapeutic Methods Can be Patentable Subject Matter
May 4, 2009 - C. Hunter Baker, MD, PhD, joins Wolf Greenfield as Counsel in our Pharmaceutical Group
March 25, 2009 - CLIENT ALERT — Federal Circuit Decision on Controversial PTO Rules
February 2009 - Maximizing Intellectual Property Value in Tough Economic Times- Seminar replay now available
November 12, 2008 - Navigating Technology Collaborations and Joint Ventures—Wolf Greenfield seminar
August 2008 - Wolf Greenfield wins three more years of patent protection for Shire Pharmaceuticals' ELAPRASE treatment
February 7, 2008 - An Entrepreneur's Guide to the Intellectual Property Galaxy
September 2007 - Pharma Patents and Licensing Are Transformed by Landmark 2007 Court Decisions, Wolf Greenfield Lawyer Tells American Chemical Society
March 29, 2007 - Wolf Greenfield Client Diomed Holdings Wins $12.5 Million Award in Patent Case - Jury Finds Two Defendants Infringed Patent for Varicose Vein Treatment
March 21, 2007 - Wolf Greenfield Names Oyer President and Managing Partner - Lawyer/Scientist Takes Reins at Boston Intellectual Property Law Firm
November 2006 - Accelerated Examination of Patent Applications: Too Good To Be True?
Q&A Booklet - Q&A on Patents
Q&A Booklet - Q&A on Intellectual Property Litigation
Q&A Booklet - Q&A on Licensing and Transactions
